Heather Wakelee, MD:The PACIFIC trial was a randomized phase III trial for patients who had unresectable stage 3 lung cancer who were treated with concurrent chemoradiation without specification of a chemotherapy regimen. And then, for those who were not progressing after completing the chemotherapy and radiation, they were randomized 2:1 to receive either durvalumab or a placebo. The study showed that the patients who ended up getting the durvalumab had a significant improvement in progression-free survival. We don’t yet have overall survival data, but the assumption would be that they would follow the progression-free survival, as they often do in studies.
The progression-free survival for the patients getting the durvalumab was in excess of 16 months. For those getting the placebo, it was less than 6 months. One of the criticisms of the trial was that the placebo group did seem to underperform historical controls. There are a lot of questions around thatsome of which are around the high numbers who had weekly carboplatin/paclitaxel without any consolidation. Carboplatin/paclitaxel—we don’t really know the answers.
A nuance point from the trial is the fact that they did include patients who had either anEGFRmutation orALKtranslocation. The numbers were fairly small, but that group did not seem to not derive benefit. They did derive benefit but not quite as much as some of the other subgroups. There also did not seem to be a difference between the chemotherapy regimens that were utilized, but there are still more questions to be asked. However, with that trial result, the United States FDA did approve durvalumab in this setting. Patients who have completed chemoradiation, who have not progressed, are then randomized to get durvalumab.
One of the things that was looked at was, how long can you wait? I think as soon as you can start the durvalumab, as soon as the patient has recovered sufficiently, it’s time to go ahead and start it. It’s an every-2-week regimen. It’s up to 1 year of therapy.
One of the big concerns everyone had before the trial results came out was around toxicity, especially around the potential for pneumonitis, or inflammation in the lung. It turned out that those rates were relatively low and not significantly different between the patients getting placebo and those who got durvalumab. There were some risks for autoimmunity or immune-related adverse events. But, again, these were relatively low. So, we do feel this is a fairly safe approach.
With the PACIFIC trial, there were a lot of questions on different subgroups and whether there were any who weren’t going to benefit. At least from the data, as they were presented, there didn’t really seem to be any group that wasn’t benefiting. Those withEGFRmutations perhaps benefited less, but they still benefited. Also, those with the highest PD-L1 levels did seem to benefit a bit more. And again, it’s all progression-free survival. We don’t yet know about overall survival. So, those with the highest levels did seem to have more of a progression-free survival, but even those with low or no PD-L1 expression did seem to benefit as well.
Transcript edited for clarity.
Nogapendekin Alfa Plus Checkpoint Inhibition Improves Survival in NSCLC
April 25th 2024Following its recent FDA approval in non-muscle-invasive bladder cancer, nogapendekin alfa has also shown overall survival benefits in addition to checkpoint inhibitor therapy in patients with non-small cell lung cancer.
Read More
Emphasizing the Need for NGS in Advanced NSCLC to Determine Treatment
April 23rd 2024During a Case-Based Roundtable® event, Joshua Sabari, MD, led a discussion on the need for next-generation sequencing to determine treatment in patients with EGFR-positive advanced non–small cell lung cancer in the first article of a 2-part series.
Read More
Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC
April 16th 2024At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making treatment decisions for patients with early-stage non–small cell lung cancer (NSCLC).
Read More